Compare iShares MSCI Japan ETF (EWJ) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Medpace Holdings Inc — how do they compare? iShares MSCI Japan ETF trades at $97.88 (market cap $23.87B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: iShares MSCI Japan ETF is the larger of the two by market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 5,412,820). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and Medpace Holdings Inc for 14 Days on average.
| EWJ | MEDP | |
|---|---|---|
Market Cap | $23.87B | $16.82B |
Volume | 5,412,820 | 223,093 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $630.19 |
52-Week Low | $78.36 | $393.42 |
Typical Hold Time | 56 Days | 14 Days |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.76, down 0.57% on the day amid mixed technical signals with a neutral overall rating. The ETF faces headwinds from Japan's monetary policy uncertainty as the Bank of Japan continues its tightening cycle, while benefiting from international equity outperformance trends in 2026. Technical indicators show the ETF trading near pivot point resistance at $98 with support at $97.
The outlook remains balanced with potential upside from Japan's AI and semiconductor exposure offset by currency volatility and rising bond yields. Key risks include yen fluctuations and global rate pressures, while institutional interest in Japanese equities provides support. The ETF's performance will hinge on BOJ policy effectiveness and sustained international market strength.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
